Thursday, July 23, 2015 3:00:58 PM
1 9,072,715 Full-Text Stable pharmaceutical composition and methods of using same
2 9,060,983 Full-Text Stable pharmaceutical composition and methods of using same
3 9,060,982 Full-Text Stable pharmaceutical composition and methods of using same
4 9,057,617 Full-Text Enhanced identification of interesting points-of-interest
5 9,057,616 Full-Text Enhanced identification of interesting points-of-interest
6 9,056,088 Full-Text Pharmaceutical compositions comprising fatty acids
7 9,046,235 Full-Text LED renewable energy lighting unit having a polygonal solar panel configuration about a horizontal or vertical pole
8 8,969,514 Full-Text Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
9 8,940,840 Full-Text Method for bonding active molecules onto a carrier, active element obtained by said method, and chemical composition for implementing said method
10 8,901,075 Full-Text Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
11 8,779,090 Full-Text Methods and compositions for the treatment of heart failure and other disorders
12 8,772,309 Full-Text Pharmaceutical formulation of apomorphine for buccal administration
13 8,765,725 Full-Text Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof
14 8,762,053 Full-Text Enhanced identification of interesting points-of-interest
15 8,741,336 Full-Text Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, Alzheimer'S disease, sleep disorders, Parkinson'S disease, AIDS, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like
16 8,716,224 Full-Text Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
17 8,710,041 Full-Text Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy
18 8,709,475 Full-Text Stable pharmaceutical composition and methods of using same
19 8,703,185 Full-Text Stable pharmaceutical composition and methods of using same
20 8,691,871 Full-Text Methods of treating mixed dyslipidemia
21 8,680,144 Full-Text Methods of treating mixed dyslipidemia
22 8,669,245 Full-Text Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
23 8,664,354 Full-Text Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
24 8,663,662 Full-Text Stable pharmaceutical composition and methods of using same
25 8,642,077 Full-Text Stable pharmaceutical composition and methods of using same
26 8,623,406 Full-Text Stable pharmaceutical composition and methods of using same
27 8,620,579 Full-Text Enhanced identification of interesting points-of-interest
28 8,618,166 Full-Text Methods of treating mixed dyslipidemia
29 8,617,594 Full-Text Stable pharmaceutical composition and methods of using same
30 8,617,593 Full-Text Stable pharmaceutical composition and methods of using same
31 8,613,945 Full-Text Stable pharmaceutical composition and methods of using same
32 8,589,069 Full-Text Enhanced identification of interesting points-of-interest
33 8,569,246 Full-Text Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
34 8,566,029 Full-Text Enhanced identification of interesting points-of-interest
35 8,563,608 Full-Text Methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
36 8,551,521 Full-Text Stable pharmaceutical composition and methods of using same
37 8,546,372 Full-Text Methods of treating hypertriglyceridemia
38 8,524,698 Full-Text Methods of treating hypertriglyceridemia
39 8,518,929 Full-Text Methods of treating hypertriglyceridemia
40 8,501,225 Full-Text Stable pharmaceutical composition and methods of using same
41 8,497,348 Full-Text Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
42 8,455,472 Full-Text Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
43 8,454,994 Full-Text Stable pharmaceutical composition and methods of using same
44 8,445,013 Full-Text Stable pharmaceutical composition and methods of using same
45 8,445,003 Full-Text Stable pharmaceutical composition and methods of using same
46 8,440,650 Full-Text Methods of treating hypertriglyceridemia
47 8,433,512 Full-Text Enhanced identification of interesting points-of-interest
48 8,431,560 Full-Text Methods of treating hypertriglyceridemia
49 8,426,399 Full-Text Methods of treating hypertriglyceridemia
50 8,415,335 Full-Text Methods of treating hypertriglyceridemia
Recent AMRN News
- Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Greece and Announces Exclusive Marketing and Commercialization Agreement with Vianex S.A. • GlobeNewswire Inc. • 05/28/2024 12:15:23 PM
- Amarin to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference • GlobeNewswire Inc. • 05/06/2024 12:00:00 PM
- Amarin Reports First Quarter 2024 Business Update and Financial Results • GlobeNewswire Inc. • 05/01/2024 11:00:00 AM
- Amarin Applauds HealthyWomen’s Citizen’s Petition Urging FDA To Take Further Action On Fenofibrate Prescribing in Patients at Risk of Cardiovascular Event • GlobeNewswire Inc. • 04/24/2024 06:00:01 PM
- Amarin Announces Results of Annual General Meeting of Shareholders • GlobeNewswire Inc. • 04/22/2024 12:00:25 PM
- Amarin to Report First Quarter 2024 Financial Results and Host Conference Call on May 1, 2024 • GlobeNewswire Inc. • 04/15/2024 12:00:00 PM
- Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24 • GlobeNewswire Inc. • 04/08/2024 12:00:00 PM
- New REDUCE-IT® Analyses Show VASCEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups • PR Newswire (Canada) • 04/08/2024 10:30:00 AM
- New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups • GlobeNewswire Inc. • 04/06/2024 07:30:00 PM
- Amarin Provides Update on VAZKEPA® (Icosapent Ethyl) Intellectual Property Portfolio in Europe • GlobeNewswire Inc. • 04/03/2024 12:00:00 PM
- Research Evaluating Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the American College of Cardiology’s (ACC) Annual Scientific Session & Expo • GlobeNewswire Inc. • 03/25/2024 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 03/04/2024 10:30:53 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 03/04/2024 01:00:24 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/29/2024 12:06:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/29/2024 12:05:56 PM
- Amarin Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update • GlobeNewswire Inc. • 02/29/2024 12:00:00 PM
- Amarin to Report Fourth Quarter and Full Year 2023 Financial Results and Host Conference on February 29, 2024 • GlobeNewswire Inc. • 02/15/2024 01:00:00 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 02/12/2024 01:00:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 09:31:50 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 09:30:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 09:30:12 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 09:30:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 09:30:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 09:30:11 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/26/2024 12:00:49 PM
PickleJar Debuts Nationwide Contest With Brian Kelley for Fans to Win a Three-Day Bahama Cruise • NREG • Jun 3, 2024 8:45 AM
ILUS Provides an Update on the Binding Term Sheet Signed with Actelis Networks (NASDAQ: ASNS) • ILUS • May 31, 2024 12:52 PM
Element79 Gold To Provide Summary and Update on Active Exploration Program, Community Relations at RMEC on June 4 • ELEM • May 30, 2024 1:18 PM
Branded Legacy Secures Exclusive Extraction Partnership with One of the World's Largest Kava Distributors and Producers • BLEG • May 30, 2024 8:30 AM
ECGI Holdings, Inc. Announces $2 Million Debt-to-Equity Conversion • ECGI • May 30, 2024 8:30 AM
North Bay Resources Reports Assays up to >25% Mg, 0.1% Ni, 0.1% Cu, 0.01% Co, 0.3 ppm Pt at Tulameen Platinum Project, British Columbia • NBRI • May 29, 2024 9:03 AM